Could a common drug ease sickle cell pain for african children?
NCT ID NCT01966731
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study tests whether hydroxyurea, a drug already used for sickle cell disease in other parts of the world, is safe and effective for children with sickle cell anemia in Africa. Children aged 1 to 10 years receive daily doses of hydroxyurea, with careful monitoring for side effects and improvements in blood counts and pain crises. The goal is to gather evidence that could make this treatment more accessible across the continent.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Hydroxyurea
What this could lead to
If successful, this could make hydroxyurea widely available for children with sickle cell anemia in Africa, reducing pain episodes and hospital visits.
What could go wrong
This is an early-phase study, so the full benefits and risks are not yet known. Hydroxyurea can lower blood cell counts, requiring careful monitoring.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier Monkole
Kinshasa, Democratic Republic of the Congo
-
Hospital Pediátrico David Bernardino
Luanda, Angola
-
KEMRI/Wellcome Trust Research
Kilifi, Kenya
-
Ministry of Health Mbale Regional Hospital
Mbale, Uganda